Rafferty Asset Management
RXRX icon

Rafferty Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Rafferty Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25M Sell
613,612
-276,983
-31% -$922K 0.01% 611
2026
Q1 		$2.73M Sell
890,595
-78,219
-8% -$302K 0.01% 540
2025
Q4 		$3.96M Buy
968,814
+218,623
+29% +$1.08M 0.01% 493
2025
Q3 		$3.66M Buy
750,191
+394,022
+111% +$2.07M 0.01% 506
2025
Q2 		$1.8M Sell
356,169
-242,251
-40% -$1.19M 0.01% 627
2025
Q1 		$3.17M Buy
598,420
+2,948
+0.5% +$21.5K 0.01% 468
2024
Q4 		$4.03M Sell
595,472
-80,319
-12% -$540K 0.01% 456
2024
Q3 		$4.45M Buy
675,791
+231,547
+52% +$1.66M 0.02% 445
2024
Q2 		$3.33M Sell
444,244
-445,995
-50% -$3.89M 0.01% 502
2024
Q1 		$8.88M Sell
890,239
-199,934
-18% -$2.23M 0.03% 311
2023
Q4 		$10.7M Sell
1,090,173
-14,353
-1% -$102K 0.05% 255
2023
Q3 		$8.45M Buy
1,104,526
+784,113
+245% +$7.82M 0.05% 267
2023
Q2 		$2.39M Sell
320,413
-129,569
-29% -$907K 0.01% 598
2023
Q1 		$3M Sell
449,982
-146,085
-25% -$1.16M 0.02% 511
2022
Q4 		$4.6M Buy
596,067
+423,541
+245% +$4.15M 0.04% 387
2022
Q3 		$1.84M Buy
172,526
+35,900
+26% +$364K 0.02% 527
2022
Q2 		$1.11M Buy
136,626
+32,977
+32% +$221K 0.01% 613
2022
Q1 		$742K Sell
103,649
-291,485
-74% -$3.1M ﹤0.01% 845
2021
Q4 		$6.77M Buy
395,134
+327,113
+481% +$6.15M 0.04% 268
2021
Q3 		$1.56M Buy
+68,021
New +$1.93M 0.01% 696

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rafferty Asset Management's RXRX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Recursion Pharmaceuticals (RXRX) stake by 31% in Q2 2026, selling an estimated $922K and leaving 613,612 shares worth $2.25M. The position accounts for 0.01% of the portfolio, ranked #611.

Rafferty Asset Management first reported a position in RXRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $10.7M in Q4 2023. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Rafferty Asset Management held 613,612 shares of Recursion Pharmaceuticals worth $2.25M as of Q2 2026.
  • Rafferty Asset Management sold 276,983 Recursion Pharmaceuticals shares in Q2 2026, an estimated $922K.
  • Recursion Pharmaceuticals made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #611 holding.
  • Rafferty Asset Management first reported a position in Recursion Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Rafferty Asset Management's Recursion Pharmaceuticals position peaked at $10.7M in Q4 2023.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.